ContraFect Corporation

6.75-0.2100-3.02%Vol 101.81K1Y Perf 28.36%
Jul 7th, 2020 10:48 DELAYED
BID6.74 ASK6.76
Open6.90 Previous Close6.96
Pre-Market- After-Market-
 - -%  - -%
Target Price
17.20 
Analyst Rating
Strong Buy 1.00
Potential %
152.20 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap103.49M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
37.91 
Earnings Date
14th Aug 2020

Today's Price Range

6.757.08

52W Range

2.6913.40

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
8.92%
1 Month
38.10%
3 Months
30.09%
6 Months
-18.81%
1 Year
28.36%
3 Years
-50.29%
5 Years
-86.87%
10 Years
-

TickerPriceChg.Chg.%
CFRX6.75-0.2100-3.02
AAPL376.953.10000.83
GOOG1 508.6612.96000.87
MSFT213.993.29001.56
XOM43.54-0.8500-1.91
WFC24.77-0.7200-2.82
JNJ143.390.41000.29
FB243.783.50001.46
GE6.78-0.2200-3.14
JPM92.67-2.3300-2.45
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.65-0.4924.62
Q04 2019-0.840.88204.76
Q03 2019-0.90-0.7022.22
Q02 2019-0.90-0.900.00
Q01 2019-1.001.50250.00
Q04 2018-1.00-0.8020.00
Q03 2018-1.00-1.000.00
Q02 2018-0.10-0.100.00
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.3351.47Positive
9/2020 QR-0.2763.01Positive
12/2020 FY-1.4247.41Positive
12/2021 FY-1.74-21.68Negative
Next Report Date14th Aug 2020
Estimated EPS Next Report-0.33
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume101.81K
Shares Outstanding15.33M
Trades Count995
Dollar Volume755.21K
Avg. Volume289.55K
Avg. Weekly Volume293.61K
Avg. Monthly Volume538.17K
Avg. Quarterly Volume353.43K

ContraFect Corporation (NASDAQ: CFRX) stock closed at 6.96 per share at the end of the most recent trading day (a -0.43% change compared to the prior day closing price) with a volume of 368.58K shares and market capitalization of 103.49M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. ContraFect Corporation CEO is Roger J. Pomerantz.

The one-year performance of ContraFect Corporation stock is 28.36%, while year-to-date (YTD) performance is 12.13%. CFRX stock has a five-year performance of -86.87%. Its 52-week range is between 2.69 and 13.4, which gives CFRX stock a 52-week price range ratio of 37.91%

ContraFect Corporation currently has a PE ratio of 14.10, a price-to-book (PB) ratio of 22.58, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -113.38%, a ROC of -189.61% and a ROE of -244.97%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ContraFect Corporation, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. ContraFect Corporation’s next earnings report date is 14th Aug 2020.

The consensus rating of Wall Street analysts for ContraFect Corporation is Strong Buy (1), with a target price of $17.2, which is +152.20% compared to the current price. The earnings rating for ContraFect Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ContraFect Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ContraFect Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 22.54, ATR14 : 0.63, CCI20 : 60.99, Chaikin Money Flow : 0.12, MACD : 0.29, Money Flow Index : 65.93, ROC : 7.57, RSI : 57.63, STOCH (14,3) : 53.57, STOCH RSI : 0.35, UO : 47.40, Williams %R : -46.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ContraFect Corporation in the last 12-months were: Cary W. Sucoff (Buy at a value of $19 500), David N. Low (Buy at a value of $129 000), Michael Messinger (Buy at a value of $1 850)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

ContraFect Corporation

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

CEO: Roger J. Pomerantz

Teplephone: +1 914 207-2300

Address: 28 Wells Avenue, Yonkers 10701, NY, USA

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

51%49%

Bearish Bullish

49%51%

News

Stocktwits